CPRX vs. ALKS
CPRX (Catalyst Pharmaceuticals, Inc.) and ALKS (Alkermes plc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, CPRX returned 48.01%/yr vs -0.05%/yr for ALKS. At a 0.23 correlation, their price movements are largely independent.
Performance
CPRX vs. ALKS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CPRX achieves a 34.02% return, which is significantly lower than ALKS's 51.72% return. Over the past 10 years, CPRX has outperformed ALKS with an annualized return of 48.01%, while ALKS has yielded a comparatively lower -0.05% annualized return.
CPRX
- 1D
- 0.03%
- 1M
- 0.42%
- YTD
- 34.02%
- 6M
- 35.06%
- 1Y
- 20.91%
- 3Y*
- 39.11%
- 5Y*
- 40.76%
- 10Y*
- 48.01%
ALKS
- 1D
- -0.82%
- 1M
- 21.32%
- YTD
- 51.72%
- 6M
- 44.34%
- 1Y
- 33.87%
- 3Y*
- 10.89%
- 5Y*
- 11.44%
- 10Y*
- -0.05%
CPRX vs. ALKS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CPRX Catalyst Pharmaceuticals, Inc. | 34.02% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
ALKS Alkermes plc | 51.72% | -2.71% | 3.68% | 6.16% | 12.34% | 16.59% | -2.21% | -30.87% | -46.08% | -1.53% |
Correlation
The correlation between CPRX and ALKS is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.39 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.35 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Nov 9, 2006 | 0.23 |
The correlation between CPRX and ALKS shifts across timeframes, from 0.23 (all time) to 0.39 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
CPRX:
$3.97B
ALKS:
$7.06B
CPRX:
$1.74
ALKS:
$0.91
CPRX:
17.98
ALKS:
46.68
CPRX:
0.32
ALKS:
0.19
CPRX:
6.67
ALKS:
4.56
CPRX:
3.92
ALKS:
4.03
CPRX:
$596.96M
ALKS:
$1.56B
CPRX:
$378.23M
ALKS:
$1.02B
CPRX:
$313.50M
ALKS:
$249.70M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CPRX vs. ALKS — Risk / Return Rank
CPRX
ALKS
CPRX vs. ALKS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Alkermes plc (ALKS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CPRX | ALKS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.21 | ||
| Sortino ratioReturn per unit of downside risk | -0.40 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.18 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 0.77 | 1.53 | -0.76 |
| Martin ratioReturn relative to average drawdown | 1.40 | 3.35 | -1.95 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CPRX | ALKS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.63 | 0.84 | -0.21 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.86 | 0.31 | +0.55 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.80 | -0.00 | +0.80 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.09 | 0.10 | -0.01 |
Drawdowns
CPRX vs. ALKS - Drawdown Comparison
The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum ALKS drawdown of -96.14%. Use the drawdown chart below to compare losses from any high point for CPRX and ALKS.
Loading charts...
Drawdown Indicators
| CPRX | ALKS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.25% | -96.14% | +1.89% |
Max Drawdown (1Y)Largest decline over 1 year | -27.29% | -22.20% | -5.09% |
Max Drawdown (3Y)Largest decline over 3 years | -27.29% | -31.58% | +4.29% |
Max Drawdown (5Y)Largest decline over 5 years | -45.37% | -33.18% | -12.19% |
Max Drawdown (10Y)Largest decline over 10 years | -64.87% | -80.58% | +15.71% |
Current DrawdownCurrent decline from peak | -0.16% | -56.71% | +56.55% |
Average DrawdownAverage peak-to-trough decline | -52.02% | -67.24% | +15.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.95% | 10.54% | +4.41% |
Volatility
CPRX vs. ALKS - Volatility Comparison
The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 0.44%, while Alkermes plc (ALKS) has a volatility of 12.00%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than ALKS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CPRX | ALKS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.44% | 12.00% | -11.56% |
Volatility (6M)Calculated over the trailing 6-month period | 23.50% | 30.15% | -6.65% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.58% | 40.67% | -7.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 47.80% | 37.28% | +10.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.47% | 41.28% | +19.19% |
Dividends
CPRX vs. ALKS - Dividend Comparison
Neither CPRX nor ALKS has paid dividends to shareholders.
Financials
CPRX vs. ALKS - Financials Comparison
This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Alkermes plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CPRX vs. ALKS - Profitability Comparison
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
ALKS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a gross profit of 0.00 and revenue of 392.91M. Therefore, the gross margin over that period was 0.0%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
ALKS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported an operating income of -48.28M and revenue of 392.91M, resulting in an operating margin of -12.3%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
ALKS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alkermes plc reported a net income of -66.48M and revenue of 392.91M, resulting in a net margin of -16.9%.
Frequently Asked Questions
CPRX and ALKS have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALKS has higher volatility (12.00%) compared to CPRX (0.44%). In terms of maximum drawdown, CPRX dropped -94.25% vs ALKS's -96.14%.
ALKS currently has the higher Sharpe Ratio (0.84 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CPRX and ALKS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer